Metástasis ganglionares inguinales palpables del melanoma

1.    National Cancer Intelligence Network. Mortality, Incidence and Gender – Malignant Melanoma. http://www.ncin.org.uk/publications/data_briefings/mortality_incidence_and_gender_malignant_melanoma [accessed 1 July 2012].
2.    Diffey BL. The future incidence of cutaneous melanoma within the UK. Br J Dermatol 2004; 151: 868–872.
3.    Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364: 2507–2516.
4.    Young SE, Martinez SR, Faries MB, Essner R, Wanek LA, Morton DL. Can surgical therapy alone achieve long-term cure of melanoma metastatic to regional nodes? Cancer J 2006; 12: 207–211.
5.    White RR, Stanley WE, Johnson JL, Tyler DS, Seigler HF. Long-term survival in 2505 patients with melanoma with regional lymph node metastasis. Ann Surg 2002; 235: 897–887.
6.    Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Ding S, Byrd DR et al. Multivariate analysis of prognostic factors among 2313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28: 2452–2459.
7.    Ives A, Poirier V, Newton-Bishop J, Verne J. Baseline Assessment of Sentinel Lymph Node Biopsy Practice Across England for Melanoma Patients, 2005–2009. National Cancer Intelligence Network: London, 2013.
8.    Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH et al.; British Association of Dermatologists Clinical Standards Unit. Revised UK guidelines for the management of cutaneous melanoma 2010. Br J Dermatol 2010; 163: 238–256.
9.    Allan CP, Hayes AJ, Thomas JM. Ilioinguinal lymph node dissection for palpable metastatic melanoma to the groin. ANZ J Surg 2008; 78: 982–986.
10.    van der Ploeg AP, van Akkooi AC, Schmitz PI, van Geel AN, de Wilt JH, Eggermont AM et al. Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Ann Surg Oncol 2011; 18: 3300–3308.
11.    Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (eds). AJCC Cancer Staging Manual (7th edn). Springer: New York, 2010.
12.    Finck SJ, Giuliano AE, Mann BD, Morton DL. Results of illoinguinal dissection for stage II melanoma. Ann Surg 1982; 2: 180–186.
13.    Coit DG, Brennan MF. Extent of lymph node dissection in melanoma of the trunk or lower extermity. Arch Surg 1989; 124: 162–166.
14.    Karakousis CP, Driscoll DL. Positive deep nodes in the groin and survival in malignant melanoma. Am J Surg 1996; 171: 421–422.
15.    Strobbe LJ, Jonk A, Hart AA, Nieweg OE, Kroon BB. Positive iliac and obturator nodes in melanoma: survival and prognostic factors. Ann Surg Oncol 1999; 6: 255–262.
16.    Mann GB, Coit DG. Does the extent of operation influence the prognosis in patients with melanoma metastatic to inguinal nodes? Ann Surg Oncol 1999; 6: 263–271.
17.    Hughes TM, A'Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg 2000; 87: 892–901.
18.    Kretschmer L, Neumann C, Preusser KP, Marsch WC. Superficial inguinal and radical ilioinguinal lymph node dissection in patients with palpable melanoma metastases to the groin – an analysis of survival and local recurrence. Acta Oncol 2001; 40: 72–78.
19.    Badgwell B, Xing Y, Gershenwald JE, Lee JE, Mansfield PF, Ross MI et al. Pelvic lymph node dissection is beneficial in subsets of patients with node-positive melanoma. Ann Surg Oncol 2007; 14: 2867–2875.
20.    Zdzienicki M, Rutkowski P, Nowecki ZI, van Akkooi ACJ, Michej W, Dziewirski W et al. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases. Eur J Surg Oncol 2013; 39: 304–310.
21.    Spillane AJ, Haydu L, McMillan W, Stretch JR, Thompson JF. Quality assurance parameters and predictors of outcome for ilioinguinal and inguinal dissection in a contemporary melanoma patient population. Ann Surg Oncol 2011; 18: 2521–2528.
22.    Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199–6206.
23.    Sterne GD, Murray DS, Grimley RP. Ilioinguinal block dissection for malignant melanoma. Br J Surg 1995; 82: 1057–1059.
24.    Bastiaannet E, Uyl-de Groot CA, Brouwers AH, van der Jagt EJ, Hoekstra OS, Oyen W et al. Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. Ann Surg 2012; 255: 771–776.
25.    Xing Y, Bronstein Y, Ross MI, Askew RL, Lee JE, Gershenwald JE et al. Contemporary diagnostic imaging modalities for the staging and surveillance of melanoma patients: a meta-analysis. J Natl Cancer Inst 2011; 103: 129–142.
26.    Hughes TM, Thomas JM. Combined inguinal and pelvic lymph node dissection for stage III melanoma. Br J Surg 1999; 86: 1493–1498.
27.    Faries MB, Thompson JF, Cochran A, Elashoff R, Glass EC, Mozzillo N et al. The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010; 17: 3324–3329.
28.    Nieweg OE. False-negative sentinel node biopsy. Ann Surg Oncol 2009; 16: 2089–2091.
29.    Jones EL, Jones TS, Pearlman NW, Gao D, Stovall R, Gajdos C et al. Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result. JAMA Surg 2013; 148: 456–461.
30.    Hoffmann-La Roche. A Study of Vemurafenib Adjuvant Therapy in Patients with Resected Cutaneous BRAF Mutant Melanoma. http://clinicaltrials.gov/show/NCT01667419 [accessed 1 August 2013].
31.    GlaxoSmithKline. A Study of the BRAF Inhibitor Dabrafenib in Combination with the MEK Inhibitor Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma After Surgical Resection. (COMBI-AD). http://clinicaltrials.gov/show/NCT01682083 [accessed 1 August 2013].
32.    Australia and New Zealand Melanoma Trials Group. Proposed Trial 1 – ANZMTG 01.12 Inguinal or Ilio-inguinal Lymphadenectomy for Patients with Metastatic Melanoma to Groin Lymph Nodes and No Evidence of Pelvic Disease on PET/CT Scan – a Randomised Phase III Trial (EAGLE FM). http://anzmtg.org/trialdetails.aspx?trialno=9 [accessed 1 August 2013].